Projects per year
Personal profile
Area of Expertise
Pre-Clinical Services evaluate new therapies against infections using animal models. These studies are done in collaboration with pharmaceutical and academic researchers, and several of these therapies are now being used clinically to treat patients.
Education/Academic qualification
MS in Biology, Fairleigh Dickinson University
BS in Microbiology, Rutgers University
Fingerprint Dive into the research topics where William Weiss is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Anti-Bacterial Agents
Medicine & Life Sciences
Staphylococcus aureus
Medicine & Life Sciences
Clostridium difficile
Medicine & Life Sciences
meropenem
Medicine & Life Sciences
Clostridium Infections
Medicine & Life Sciences
Piperacillin
Medicine & Life Sciences
Infection
Medicine & Life Sciences
Carbapenems
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2011 2020
Development and Validation of a Chronic Murine Lung Infection Model with P. aeruginosa
18/04/19 → 17/04/20
Project: Research
TP-6076 Single Dose Pharmacokinetic Study in Mice for Ex Vivo Plasma Protein Binding
Tetraphase Pharmaceuticals Inc.
1/10/18 → 30/09/19
Project: Research
PK/PD of Novel Test Article(s) in the Murine Thigh Infection Model with Klebsiella pneumoniae isolates
28/08/18 → 27/08/19
Project: Research
Research Output 1985 2019
- 2002 Citations
- 24 h-Index
- 53 Article
In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection
Weiss, W., Pulse, M. E., Nguyen, P. & Growcott, E. J., 1 Apr 2019, In : Antimicrobial agents and chemotherapy. 63, 4, e02214-18.Research output: Contribution to journal › Article
Klebsiella Infections
Monobactams
Carbapenems
Klebsiella pneumoniae
Uranyl Nitrate
1
Citation
(Scopus)
Pharmacological, toxicological, and dose range assessment of OG716, a novel lantibiotic for the treatment of clostridium difficile-associated infection
Pulse, M. E., Weiss, W., Kers, J. A., DeFusco, A. W., Park, J. H. & Handfield, M., 1 Apr 2019, In : Antimicrobial agents and chemotherapy. 63, 4, e01904-18.Research output: Contribution to journal › Article
Bacteriocins
Clostridium difficile
Toxicology
Pharmacology
Mesocricetus
Treatment and prevention of recurrent Clostridium difficile infection with functionalized bovine antibody-enriched whey in a hamster primary infection model
Heidebrecht, H. J., Weiss, W., Pulse, M., Lange, A., Gisch, K., Kliem, H., Mann, S., Pfaffl, M. W., Kulozik, U. & von Eichel-Streiber, C., 1 Feb 2019, In : Toxins. 11, 2, 98.Research output: Contribution to journal › Article
Open Access
Clostridium Infections
Clostridium
Clostridium difficile
Cricetinae
Antibodies
6
Citations
(Scopus)
Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis
Weiss, W., Pulse, M. E., Nguyen, P., Peterson, K., Silva, J., Simecka, J., Valtierra, D., Sabet, M. & Griffith, D. C., 1 Jan 2018, In : Antimicrobial agents and chemotherapy. 62, 1, e01439.Research output: Contribution to journal › Article
meropenem
Carbapenems
Pyelonephritis
Enterobacteriaceae
Klebsiella pneumoniae
1
Citation
(Scopus)
Antibiotic-induced dysbiosis predicts mortality in an animal model of clostridium difficile infection
Burdet, C., Sayah-Jeanne, S., Nguyen, T. T., Hugon, P., Sablier-Gallis, F., Saint-Lu, N., Corbel, T., Ferreira, S., Pulse, M., Weiss, W., Andremont, A., Mentré, F. & De Gunzburg, J., 1 Oct 2018, In : Antimicrobial agents and chemotherapy. 62, 10, e00925.Research output: Contribution to journal › Article
Dysbiosis
Clostridium Infections
Clostridium difficile
Animal Models
Anti-Bacterial Agents